Physician profile
Charles M Grade
NPI 1790890796
$710.26
in general payments reported to CMS, 2019-2025
13 companies · $56.84 in 2025
The $56.84 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2021: $93.97 · 2022: $41.08 · 2023: $50.27 · 2024: $158 · 2025: $56.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $239.24 | 2019-2024 | Aristada, Lybalvi |
| Allergan, INC. | $130.99 | 2019 | |
| Neurocrine Biosciences, INC. | $92.31 | 2021-2025 | Ingrezza |
| Abbvie INC. | $54.53 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Axsome Therapeutics, INC. | $24.99 | 2024 | Auvelity |
| Indivior INC. | $21.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2024 | Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $16.89 | 2025 | Cobenfy |
| Shire North American Group INC | $16.82 | 2019 | |
| Adlon Therapeutics L.P. | $15.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Grade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.